Cogent Biosciences, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cogent Biosciences, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
  • Cogent Biosciences, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 16.1 %, a 5.84% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 16.1 +0.89 +5.84% Jun 30, 2024
Q1 2024 15.5 -0.43 -2.71% Mar 31, 2024
Q4 2023 16.9 +2.46 +17% Dec 31, 2023
Q3 2023 16 +3.65 +29.5% Sep 30, 2023
Q2 2023 15.2 +4.16 +37.6% Jun 30, 2023
Q1 2023 15.9 +7.18 +82.4% Mar 31, 2023
Q4 2022 14.5 +7.11 +96.6% Dec 31, 2022
Q3 2022 12.4 +5.38 +76.9% Sep 30, 2022
Q2 2022 11.1 +0.86 +8.42% Jun 30, 2022
Q1 2022 8.71 -4.96 -36.3% Mar 31, 2022
Q4 2021 7.36 -17.9 -70.9% Dec 31, 2021
Q3 2021 6.99 -115 -94.3% Sep 30, 2021
Q2 2021 10.2 -58.1 -85.1% Jun 30, 2021
Q1 2021 13.7 -57.6 -80.8% Mar 31, 2021
Q4 2020 25.3 -47.3 -65.2% Dec 31, 2020
Q3 2020 122 +56.5 +86.3% Sep 30, 2020
Q2 2020 68.3 +15.5 +29.4% Jun 30, 2020
Q1 2020 71.3 +27.5 +63% Mar 31, 2020
Q4 2019 72.6 -1.81 -2.43% Dec 31, 2019
Q3 2019 65.5 -233 -78% Sep 30, 2019
Q2 2019 52.8 Jun 30, 2019
Q1 2019 43.7 Mar 31, 2019
Q4 2018 74.4 Dec 31, 2018
Q3 2018 298 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.